|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reserpine#Warnings]] |
| {{Reserpine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Precautions==
| |
| | |
| ===General===
| |
| | |
| Since reserpine increases gastrointestinal motility and secretion, it should be used cautiously in patients with a history of [[peptic ulcer]], [[ulcerative colitis]], or [[gallstones ]]([[biliary colic]] may be precipitated).
| |
| | |
| Caution should be exercised when treating hypertensive patients with renal insufficiency, since they adjust poorly to lowered blood pressure levels.
| |
| | |
| Preoperative withdrawal of reserpine does not assure that circulatory instability will not occur. It is important that the anesthesiologist be aware of the patient’s drug intake and consider this in the overall management, since [[hypotension ]]has occurred in patients receiving [[rauwolfia ]]preparations. Anticholinergic and/or adrenergic drugs (e.g., [[metaraminol]], [[norepinephrine]]) have been employed to treat adverse vagocirculatory effects.
| |
| | |
| ===Information for Patients===
| |
| | |
| Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.
| |
| | |
| ===Drug Interactions===
| |
| | |
| MAO inhibitors should be avoided or used with extreme caution.
| |
| | |
| Concurrent use of [[tricyclic antidepressants]] may decrease the antihypertensive effect of reserpine.
| |
| | |
| Concurrent use of reserpine and direct-or-indirect acting sympathomimetics should be closely monitored. The action of direct-acting amines ([[epinephrine]], [[isoproterenol]], [[phenylephrine]], [[metaraminol]]) may be prolonged when given to patients taking reserpine. The action of indirect-acting amines ([[ephedrine]], [[tyramine]], [[amphetamines]]) is inhibited.
| |
| | |
| Reserpine should be used cautiously with digitalis and quinidine, since cardiac arrhythmias have occurred with rauwolfia preparations.
| |
| | |
| Concomitant use of reserpine with other [[antihypertensive ]]agents necessitates careful titration of dosage with each agent.
| |
| | |
| | |
| | |
| ===Pregnancy Category C===
| |
| | |
| Reserpine administered parenterally has been shown to be teratogenic in rats at doses up to 2 mg/kg and to have an embryocidal effect in guinea pigs given dosages of 0.5 mg daily.
| |
| | |
| There are no adequate and well-controlled studies of reserpine in pregnant women. Reserpine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ====Nonteratogenic Effects====
| |
| | |
| Reserpine crosses the placental barrier, and increased respiratory tract secretions, [[nasal congestion]], [[cyanosis]], and [[anorexia ]]may occur in [[neonates ]]of reserpine-treated mothers.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Reserpine is excreted in maternal breast milk, and increased respiratory tract secretions, nasal congestion, [[cyanosis]], and [[anorexia ]]may occur in breast-fed infants. Because of the potential for adverse reactions in nursing infants and the potential for tumorigenicity shown for reserpine in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in children have not been established by means of controlled clinical trials, although there is experience with the use of reserpine in children (see [[Reserpine dosage and administration|DOSAGE AND ADMINISTRATION]].) Because of adverse effects such as emotional depression and lability, sedation, and stuffy nose, reserpine is not usually recommended as a step-2 drug in the treatment of hypertension in children.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESERPINE TABLET [EON LABS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |